Destiny Pharma (LON:DEST) CEO Neil Clark spoke with Proactive at the Biotech Showcase 2020 in San Francisco. The UK-based, clinical phase biotechnology company is focused on preventing post-surgical infection in a Phase 2b clinical trial with its lead asset. According to its website, Destiny is building a portfolio of antimicrobial drug products that to combat the threat of antimicrobial resistance (AMR).
Destiny Pharma awaits key inflection point mid--2020 in its antimicrobial Phase 2b clinical trial
Quick facts: Destiny Pharma plc
Price: 36.5 GBX
Market Cap: £16.01 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...FOR OUR FULL DISCLAIMER CLICK HERE